C3N-04168
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 51.27173169
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.490
- IL6_JAK_STAT3_SIGNALING+0.450
- ANGIOGENESIS+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- KRAS_SIGNALING_UP+0.320
- INFLAMMATORY_RESPONSE+0.300
- COMPLEMENT+0.290
- APICAL_SURFACE+0.280
- IL2_STAT5_SIGNALING+0.280
- INTERFERON_GAMMA_RESPONSE+0.260
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- OXIDATIVE_PHOSPHORYLATION-0.450
- E2F_TARGETS-0.420
- CHOLESTEROL_HOMEOSTASIS-0.380
- G2M_CHECKPOINT-0.340
- DNA_REPAIR-0.330
- FATTY_ACID_METABOLISM-0.330
- MYC_TARGETS_V1-0.300
- UV_RESPONSE_UP-0.250
- SPERMATOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-03976 | — | cohortMD2 | 0.861 |
| 2 | 6bf9821d-da67-470f-9650-69d05b056166 | — | — | 0.847 |
| 3 | cf9ea065-c101-48e2-a1ea-54eb01658eef | — | — | 0.844 |
| 4 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.840 |
| 5 | TCGA-69-7978-01A-11R-2187-07 | — | cohortA1 | 0.837 |
| 6 | TCGA-44-2665-01A-01R-0946-07 | — | cohortA1 | 0.836 |
| 7 | TCGA-55-6971-01A-11R-1949-07 | — | cohortMD2 | 0.834 |
| 8 | SRR8518195 | — | A | 0.829 |
| 9 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.827 |
| 10 | SRR8518350 | — | A | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |